British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...

(Reuters) - GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...

DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...